Biotech Innovations In The Face of Economic Uncertainty

While the pharmaceutical industry has traditionally been seen as recession-proof, with a constant demand for medicines and new treatment options, it currently faces significant challenges. Economic uncertainty is on the rise, increasing the risks associated with early drug discovery, clinical trials, quality and manufacturing processes, and regulatory approval. These risks, coupled with the looming possibility […]

Overcoming Challenges In Biopharma Novel Drug Manufacturing

The biopharmaceutical sector is undergoing a significant transformation in treating complex diseases, especially in oncology, driven by innovative drug approaches. This shift entails personalized therapies, combination treatments, and novel go-to-market strategies to address specific patient groups. As the industry expands, companies must acknowledge the upcoming changes and obstacles, including supply-demand dynamics and industry trends. Novel […]

Boosting Innovation And Value In UK Biopharma And Medtech

New recommendations from Imperial College London aim to boost competitiveness in the UK’s biopharma and Medtech sectors. It assesses the value-added per capita in these sectors and provides insights into their needs, challenges, and opportunities. Technological solutions and policy recommendations are identified as crucial for increasing innovation and value-added. It emphasizes the need for collaboration […]

Biopharma Spectrum To Be Driven By Automation In Next Decade

One of the reports concerning automation in the biopharmaceutical sector has gone on to show that the market is estimated to grow at a CAGR of 5.7% during the forecast period of 2023–2033. According to the data, the market’s global revenue value is expected to cross $1855 million this year. The report also found out […]

What’s driving the growth of the biopharma sector across South East Asia?

Standfirst: The healthcare industry, particularly the life-science and biopharma sectors, across ASEAN is seeing a shift away from a reliance on overseas expertise and imported products and technology towards a preference for homegrown solutions. T he growth in South East Asia’s healthcare industry used to be largely driven by the region’s increasing affluence, growing educated […]

Enhanced Biopharmaceutical Release: Autonomous PAT Power

Speeding up biomanufacturing using automated Process Analytical Technology (PAT) systems A2P2 and Micro Sequential Injection (SI), two cutting-edge process analysers, have been cited as autonomous PAT platform that enables quick testing and release of biopharmaceutical products. An insight has showcased two innovative, automated, real-time sample acquisition and preparation systems for monitoring, controlling, and releasing biopharmaceuticals […]

Key Steps For Biopharma Startups Getting Ready For EU HTA

What is the Joint European HTA? Navigating pricing and reimbursement in the European Union (EU) can be a complex task for emerging biopharmaceutical companies (EBPs), defined as those with less than $200 million in estimated annual R&D spending or global revenue below $500 million. With 27 countries each having their unique application requirements, languages, dossier […]

Biopharma & Healthcare In Asia-Pacific – Leveraging Ties

In the last five years, there have been various local governments in the Asia-Pacific region that have enacted beneficial policies and also regulatory frameworks to push healthcare and expedite drug development in their respective markets. These initiatives have contributed immensely to improving collabs within the industry. The R&D Focus Governments are indeed showcasing a strong […]

M&A Revival In The Biopharmaceutical Sector Back On Track

It is worth noting that the biopharmaceutical sector has gone on to experience a revival when it comes to mergers and acquisitions in the second half of 2023. One can see three major reasons resulting in this uptick in deal-making intensity: pharmaceutical companies looking for pipeline diversity as a result of the Inflation Reduction Act- […]

Lack of Experience Hinders CDMOs In Cell And Gene Therapy

CDMOs (contract development and manufacturing organizations) are facing challenges due to the increasing number of companies preparing to scale up their cell and gene therapy manufacturing for Phase III trials and commercialization. While physical capacity has been blamed, the real issue lies in the lack of experience. Manufacturing novel products requires process innovation, but advanced […]